Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2029

DESCRIPTION
TABLE OF CONTENTS
COMPANIES MENTIONED

1 of 3

FEATURED COMPANIES

AbbVie Inc.
Allergan plc. Amgen Inc.
AstraZeneca plc.
F. Hoffmann-La Roche Ltd
FibroGen
GlaxoSmithKline plc.
MORE

Chronic kidney disease (CKD) is also known as chronic kidney failure or renal disease is a condition characterized by a gradual loss of kidney function over time. Key market determinant include rising geriatric populace, increment in prevalence of CKD and favorable insurance policies in developed economies.

The report titled “Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2019-2029” provides detailed insights into key market determinants that impacted the market across geographies and drug types. The report also includes market estimation and forecast for CKD drugs for geographic region for 2019 -2029. The forecast period was 2021 to 2029, historic period included 2019 and base year 2020. The drug class considered in the report was antihypertensive, antihyperlipidemic, anemia treatment drugs, swelling treatment drugs and other medications. The report provides in-depth analysis on each market segment across drug classes and geographies and estimates that would enable the decision makers to make pre informed decisions.

Geographically, the global chronic kidney disease (CKD) drugs market is studied for the following regional markets:

North America

U.S.
Canada

Europe

U.K.
Germany
Rest of Europe

Asia-Pacific

China
Japan
Rest of Asia Pacific

Latin America

Middle East and Africa

The report also includes exhaustive qualitative study and analysis on key determinants, impact of the macro factors that impacted the market in short, medium and long term future. The report throws light on various opportunities across different market segments and geographies. The report includes the impact of covid 19 on the CKD market interms of diagnosis and treatment. The pandemic had a significant impact on the market due to limited access to healthcare services. The report provides detailed competitive analysis with respect to key market players. The analysis includes from basic profiling to key market intelligence and strategies such as product launches, drug approvals, mergers & acquisitions, strategic partnerships and other key strategies that were deployed by market players to enhance their market presence across geographies.

Based on drug class, the global chronic kidney disease (CKD) drugs market is segmented as follows:

Antihypertensive
ACE Inhibitors
Angiotensin-II Receptor Blockers
Beta Blockers
Calcium Channel Blockers
Diuretics
Anemia Treatment Drugs
Antihyperlipidemic Drugs
Swelling Treatment Drugs
Other

Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population. More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2019. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.

For the purpose of this study, the global chronic kidney disease (CKD) drugs market is categorized into:

North America
Europe
Asia Pacific
Latin America (LATAM)
Middle East and Africa(MEA)

North America was the market leader interms of market revenues for CKD drugs market in 2019 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing in obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs. As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2021 to 2029. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.

Note: Product cover images may vary from those shown

2 of 3

FEATURED COMPANIES

AbbVie Inc.
Allergan plc. Amgen Inc.
AstraZeneca plc.
F. Hoffmann-La Roche Ltd
FibroGen
GlaxoSmithKline plc.
MORE

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Chronic Kidney Disease (CKD) Drugs Market Snapshot
2.2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2019 (US$ Bn)
2.3 Global Chronic Kidney Disease (CKD) Drugs Market Share, by Geography, 2019 (Value %)
2.4 Impact of covid 19

Chapter 3 Chronic Kidney Disease (CKD) Drugs Market Analysis
3.1 Global Chronic Kidney Disease (CKD) Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 High prevalence of Chronic Kidney Disease (CKD)
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Chronic Kidney Disease (CKD) Drugs Market

Chapter 4 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class
4.1 Overview
4.2 Antihypertensive
4.3 Antihyperlipidemic
4.4 Anemia Treatment Drugs
4.5 Swelling Treatment Drugs
4.6 Other

Chapter 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.2 Allergan plc.
6.3 Amgen Inc.
6.4 AstraZeneca plc.
6.5 F. Hoffmann-La Roche Ltd
6.6 FibroGen
6.7 GlaxoSmithKline plc.
6.8 Johnson & Johnson
6.9 Keryx Biopharmaceuticals, Inc.
6.10 Kissei Pharmaceutical Co., Ltd
6.11 Pfizer, Inc.
6.12 Sanofi S.A.
6.13 Teva Pharmaceutical Industries Ltd.

List of Figureres
Figure 1 Chronic Kidney Disease (CKD) Drugs Market: Research Methodology
Figure 2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2019 (US$ Bn)
Figure 3 Global Chronic Kidney Disease (CKD) Drugs Market Share, by Geography, 2019 (Value %)
Figure 4 Attractive Investment Proposition: Global Chronic Kidney Disease (CKD) Drugs Market, by Geography, 2016
Figure 5 Global Antihypertensive Market for Chronic Kidney Disease (CKD) Drugs, 2019-2029(US$ Bn)
Figure 6 Global Antihyperlipidemic Market for Chronic Kidney Disease (CKD) Drugs, 2019-2029(US$ Bn)
Figure 7 Global Anemia Treatment Drugs Market for Chronic Kidney Disease (CKD) Drugs, 2019-2029(US$ Bn)
Figure 8 Global Swelling Treatment Drugs Market for Chronic Kidney Disease (CKD) Drugs, 2019-2029 (US$ Bn)
Figure 9 Global Other Medication Market for Chronic Kidney Disease (CKD) Drugs, 2019-2029 (US$ Bn)
Figure 10 Latin America Chronic Kidney Disease (CKD) Drugs Market, 2019-2029 (US$ Bn)
Figure 11 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2019-2029 (US$ Bn)

List of Tables
Table 1 Market Positioning of Key Players in Global Chronic Kidney Disease (CKD) Drugs Market
Table 2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2019-2029(US$ Bn)
Table 3 Global Chronic Kidney Disease (CKD) Drugs Market, by Geography, 2019-2029(US$ Bn)
Table 4 North America Chronic Kidney Disease (CKD) Drugs Market, 2019-2029(US$ Bn)
Table 5 Europe Chronic Kidney Disease (CKD) Drugs Market, 2019-2029(US$ Bn)
Table 6 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2019-2029(US$ Bn)
Table 7 AbbVie, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 8 Allergan plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 9 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 10 AstraZeneca plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 11 F. Hoffmann-La Roche Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 12 FibroGen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 13 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 14 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 15 Keryx Biopharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 16 Kissei Pharmaceutical Co., Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 18 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 19 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Note: Product cover images may vary from those shown

3 of 3

AbbVie Inc.
Allergan plc. Amgen Inc.
AstraZeneca plc.
F. Hoffmann-La Roche Ltd
FibroGen
GlaxoSmithKline plc.
Johnson & Johnson
Keryx Biopharmaceuticals Inc.
Kissei Pharmaceutical Co. Ltd.
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

FEATURED COMPANIES

RELATED TAGS

RELATED PRODUCTS

Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029

Chronic Kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - 2030

Chronic Kidney Disease-Anemia - Epidemiology Forecast to 2029

Late-stage chronic kidney disease (CKD) - Pipeline Insight, 2020

Chronic Kidney Disease (CKD) - Epidemiology Forecast to 2030